Dr Masahito Tsuboi spoke to ecancer online about the ADAURA study presented at ESMO 2020 meeting this year.
He first talked about the rationale behind using osimertinib as adjuvant therapy on patients with early stage EGFRm NSCLC, after tumour resection.
He further explained how the study was evaluated and the key results that were observed with regards to overall survival and disease progression.
He also talked about sites of disease recurrence and how they impacted survival.
Lastly, Dr. Tsuboi wrapped up with the future implications of this study in terms of clinical care for EGFRm NSCLC.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.